Executive Summary
Veramed is a B Corp certified, biometric-specialist Clinical Research Organization (CRO) dedicated to delivering ethical, high-quality clinical research through a specialized focus on data management, statistical programming, and biostatistics. Committed to patient-centric, high-impact biometric research, Veramed has established a strategic partnership with Medidata centered on cultural alignment and technical excellence. By leveraging Medidata’s market-leading technology, Veramed enhances its ability to manage complex clinical trials, particularly in therapeutic areas including oncology, respiratory, and rare disease. By achieving Medidata accreditations, Veramed directly streamlines its workflows and cuts project timelines, setting the stage for future AI and patient-focused data initiatives.The Challenge
As a specialized CRO, Veramed focuses exclusively on biometrics—data management and analytics, statistical programming, and statistics. However, managing large-scale, multinational Phase 3 trials requires sophisticated infrastructure and specialized tools, such as Randomization and Trial Supply Management (RTSM), which are complex to build in-house. Veramed needed a way to provide a "complete package" to sponsors while maintaining its rigorous standards for data integrity and high-quality biometric output without the overhead of building every technical system from scratch.
"There is a symbiotic relationship between our companies grounded in a shared culture of transparent communication and connection. We’ve eradicated the silos and it’s a very, well-oiled and smooth relationship, which enables us to meet challenging timelines, and also deal with complexities to ensure the clients get what they need."
— Claude Price, Senior Director Data Management, Veramed |
The Solution
Veramed formalized its relationship with Medidata by becoming an accredited partner in Rave and Coder. This strategic alliance allows Veramed to leverage Medidata’s expertise and robust technical environment to handle complex study requirements. Another key component of the solution is the utilization of Medidata’s RTSM, where Veramed takes full accountability of deployment, via oversight and management of the supply process, while relying on Medidata’s in-house programmers for the build. This symbiotic relationship ensures that Veramed can offer full-service biometric capabilities backed by a trusted, globally recognized technology platform.Results and Benefits
- Enhanced Efficiency: Technical initiatives have significantly reduced timelines; data management and statistical programming tasks that previously took two days can now be completed in 6-7 hours.
- Cultural and Ethical Alignment: As a B Corp, Veramed prioritizes ethical and wellbeing standards and employee retention (94%), finding a strong synergy in Medidata’s relationship-driven culture and mutual respect.
- Quality Assurance: Utilizing a market-leading system provides "peace of mind" regarding data integrity and validation, which is critical under evolving ICH E6 (R3) guidelines.
- Scalability: The partnership has enabled Veramed to embrace large portfolios of studies, including management of significant, multi-year multinational Phase 3 trials.